-
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)
Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
KO Validated Antibodies(Page)KO Validated Antibodies | Assay Genie
Hepatocellular Carcinoma - Methyltransferase expression(Post)Hepatocellular carcinoma (HCC) is one of the most frequently occurring cancers and there are 630,000 new cases diagnosed every year worldwide (De Minicis et al. 2013). HCC develops frequently fr
Alzheimer's Disease: A Comprehensive Insight(Post)Alzheimer's disease stands as a formidable challenge in the realm of neurological disorders, characterized by its progressive nature and profound impact on cognitive functions. This article delve
Immunoglobulin vs Antibody: Unveiling the Intricacies(Post)In the realm of immunology, the terms "immunoglobulin" and "antibody" often find themselves used interchangeably, sparking confusion among those keen on understanding the immune system's fine deta
Innate Lymphoid Cells: ILC1, ILC2 & ILC3(Page) Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution(Post)Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution Imagine being able to create a detailed map of a city, not just showing the streets and buildings, but also revealing th
In Vivo depletion atlas(Page) Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
The Lenti Viral Vector System: A New Way to Deliver Genetic Therapies(Post)Gene Delivery · Viral VectorsLentiviral Vectors: Design, Production and Use in Gene DeliveryLentiviral vectors integrate their cargo into the host genome and transduce dividing and non-dividing cells
Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research(Post)Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
SfN Neuroscience 2024(Post)SfN 2024: Meet Assay Genie at the Society for NeuroscienceAssay Genie is delighted to be attending SfN 2024 in Chicago, Illinois on 5th to the 9th of October at the McCormick Convention
Prostate Cancer Markers : What to Look for in Your Test Results(Post)In this blog post, we will review prostate cancer markers and what you should look for in your results. Prostate antigen marker (PSA) and p63 are the most common markers found in pro
Understanding CD16: A Comprehensive Overview(Post)CD16, also known as FcγRIII (Fc gamma receptor III), plays a crucial role in the immune system, serving as a receptor for the Fc region of immunoglobulin G (IgG). This receptor is a key player in
Mitochondrial Transplantation: A New Frontier in Restoring Neural Function After Ischemic Stroke(Post)Imagine a future where the devastating impact of a stroke could be significantly mitigated, not just by managing symptoms, but by directly repairing the cellular machinery damaged during the event. T
Binding Is the Easy Part(Post)An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci